The company said that it plans to assess whether there is an opportunity to continue development of CTI-01 with a collaborative partner or to out-license the drug. Critical Therapeutics licensed patent rights related to CTI-01 from the University of Pittsburgh and Xanthus Pharmaceuticals.
The results from this double-blind, placebo-controlled trial covered the 102 patients enrolled in the trial prior to March 15, 2006 when the company discontinued the trial due to a manufacturing issue related to the drug container closure system.